{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:56:07Z","timestamp":1778255767333,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.3816\/cgc.2009.n.002","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T21:01:42Z","timestamp":1234472502000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non\u2013Renal Cell Carcinoma: A Meta-analysis"],"prefix":"10.3816","volume":"7","author":[{"given":"David","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2009.n.002_bib1","first-page":"471","article-title":"SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CGC.2009.n.002_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":"SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model","volume":"20","author":"Murray","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"10.3816\/CGC.2009.n.002_bib3","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CGC.2009.n.002_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-004-3149-y","article-title":"The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels","volume":"7","author":"Osusky","year":"2004","journal-title":"Angiogenesis"},{"key":"10.3816\/CGC.2009.n.002_bib5","first-page":"4009","article-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models","volume":"63","author":"Schueneman","year":"2003","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2009.n.002_bib6","first-page":"614","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"94","author":"Patel","year":"2006","journal-title":"BrJCancer"},{"key":"10.3816\/CGC.2009.n.002_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.002_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ctrv.2007.09.003","article-title":"New developments in multitargeted therapy for patients with solid tumours","volume":"34","author":"Le Tourneau","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CGC.2009.n.002_bib9","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.3816\/CGC.2009.n.002_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib vs interferon alfa in metastatic renal cell cancer","volume":"356","author":"Motzer","year":"2007","journal-title":"N Eng J Med"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib11","first-page":"223s","article-title":"Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study","volume":"25","author":"Bang","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CGC.2009.n.002_bib13","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3816\/CGC.2006.s.004","article-title":"Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma","volume":"5","author":"Speca","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.3816\/CGC.2009.n.002_bib14","author":"National Cancer Institute"},{"key":"10.3816\/CGC.2009.n.002_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.3816\/CGC.2009.n.002_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.3816\/CGC.2009.n.002_bib17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.3816\/CGC.2009.n.002_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinb in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib19","first-page":"237s","article-title":"Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment in an expanded access trial with subpopulation analysis","volume":"25","author":"Gore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib20","first-page":"550s","article-title":"Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy","volume":"25","author":"Reichardt","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib21","first-page":"222s","article-title":"Efficacy and safety of sunitinib malate (SU11248, Sutent) in bevacizumab-refractory metastatic renal cell carcinoma","volume":"24","author":"Rini","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib22","first-page":"244s","article-title":"Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: updated results","volume":"25","author":"Srinivas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib23","first-page":"548s","article-title":"Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST","volume":"25","author":"George","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.002_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncologica"},{"key":"10.3816\/CGC.2009.n.002_bib25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","article-title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?","volume":"42","author":"Strumberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CGC.2009.n.002_bib26","first-page":"753","article-title":"Capecitabine: nursing implications of a new oral chemotherapeutic agent","volume":"26","author":"Mrozek-Orlowski","year":"1999","journal-title":"Oncol Nurs Forum"},{"key":"10.3816\/CGC.2009.n.002_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/1523-1747.ep12371787","article-title":"Epithelial-stromal interactions in basal cell cancer: the PDGF system","volume":"102","author":"Ponten","year":"1994","journal-title":"J Invest Dermatology"},{"key":"10.3816\/CGC.2009.n.002_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","article-title":"Expression of C-Kit and Kit ligand proteins in normal human tissues","volume":"42","author":"Lammie A Drobnjak","year":"1994","journal-title":"J Histochem Cytochem"},{"key":"10.3816\/CGC.2009.n.002_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00387600","article-title":"Expression of c-kit ligand in human keratinocytes","volume":"286","author":"Morita","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.3816\/CGC.2009.n.002_bib30","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor(VEGF) and vascular endothelial growth factor receptor(VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CGC.2009.n.002_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"10.3816\/CGC.2009.n.002_bib32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.3816\/CGC.2009.n.002_bib33","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/1523-1747.ep12348498","article-title":"Activation of Raf-mitogen-activated proteinkinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes","volume":"106","author":"Gniadecki","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CGC.2009.n.002_bib34","doi-asserted-by":"crossref","first-page":"41011","DOI":"10.1074\/jbc.M003716200","article-title":"Ras-independent activation of the Raf\/MEK\/ERK pathway upon calcium-induced differentiation of keratinocytes","volume":"275","author":"Schmidt","year":"2000","journal-title":"J Biol Chem"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib35","first-page":"494s","article-title":"Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: results of a randomized double-blind placebo-controlled study","volume":"25","author":"Lee","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib36","first-page":"243s","article-title":"The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)","volume":"25","author":"Stadler","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.002_bib37","first-page":"254s","article-title":"Phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma","volume":"15","author":"Gallagher","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.002_bib38","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:23Z","timestamp":1761564023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311700088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1558767311700088"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2009.n.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non\u2013Renal Cell Carcinoma: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2009.n.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}